Quick Takeaways
- Foresite Capital Fund IV, L.P. filed SCHEDULE 13G/A for Lyell Immunopharma, Inc. Common Stock, par value $0.0001 (LYEL).
- Disclosed ownership: 7.6%.
- Date of event: 30 Sep 2025.
Quoteable Key Fact
"Foresite Capital Fund IV, L.P. disclosed 7.6% ownership in Lyell Immunopharma, Inc. Common Stock, par value $0.0001 (LYEL) on 30 Sep 2025."
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original Filing| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Foresite Capital Fund IV, L.P. | 4.2% | 800,339 | 800,339 | 0 | /s/ James Tananbaum | James Tananbaum, Managing Member of the General Partner | |
| Foresite Capital Management IV, LLC | 4.2% | 800,339 | 800,339 | 0 | /s/ James Tananbaum | James Tananbaum, Managing Member | |
| Foresite Capital Fund V, L.P. | 2.5% | 477,078 | 477,078 | 0 | /s/ James Tananbaum | James Tananbaum, Managing Member of the General Partner | |
| Foresite Capital Management V, LLC | 2.5% | 477,078 | 477,078 | 0 | /s/ James Tananbaum | James Tananbaum, Managing Member | |
| Foresite Capital Opportunity Fund V, L.P. | 0.9% | 177,199 | 177,199 | 0 | /s/ James Tananbaum | James Tananbaum, Managing Member of the General Partner | |
| Foresite Capital Opportunity Management V, LLC | 0.9% | 177,199 | 177,199 | 0 | /s/ James Tananbaum | James Tananbaum, Managing Member | |
| James B. Tananbaum | 7.6% | 1,454,616 | 1,454,616 | 0 | /s/ James Tananbaum | James Tananbaum |